Cargando…
Systematic druggable genome-wide Mendelian randomisation identifies therapeutic targets for Alzheimer’s disease
BACKGROUND: Alzheimer’s disease (AD) is the leading cause of dementia. Currently, there are no effective disease-modifying treatments for AD. Mendelian randomisation (MR) has been widely used to repurpose licensed drugs and discover novel therapeutic targets. Thus, we aimed to identify novel therape...
Autores principales: | Su, Wei-Ming, Gu, Xiao-Jing, Dou, Meng, Duan, Qing-Qing, Jiang, Zheng, Yin, Kang-Fu, Cai, Wei-Chen, Cao, Bei, Wang, Yi, Chen, Yong-Ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579488/ https://www.ncbi.nlm.nih.gov/pubmed/37349091 http://dx.doi.org/10.1136/jnnp-2023-331142 |
Ejemplares similares
-
Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19
por: Gaziano, Liam, et al.
Publicado: (2021) -
No genetic causal association between dental caries and Alzheimer’s disease: a bidirectional two-sample Mendelian randomization analysis
por: Liao, Qiao, et al.
Publicado: (2023) -
Potential therapeutic targets for sarcopenia identified by Mendelian randomisation
por: Jiang, Wei, et al.
Publicado: (2023) -
Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials
por: Yu, Jin-Tai, et al.
Publicado: (2020) -
Peripheral level of CD33 and Alzheimer’s disease: a bidirectional two-sample Mendelian randomization study
por: Gu, Xiaojing, et al.
Publicado: (2022)